Stay updated with breaking news from Oral Formulation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer’s oral COVID-19 antiviral has cut the risk of hospitalization or death by 85% in a late-phase trial, prompting the Big Pharma to stop the study and race to seek emergency use authorization from the FDA.
The Postoperative Pain Management Market To Step Into The Shoes Of Innovation
/PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that five presentations on amyotrophic lateral sclerosis (ALS) will be shared as...
The Next 10 Years To See The Cushings Syndrome And Acromegaly Treatment Market Go Exponential Ways (Reaching US$ 1,834.2 Million)
The Next 10 Years To See The Cushings Syndrome And Acromegaly Treatment Market Go Exponential Ways (Reaching US$ 1,834.2 Million)